Durvalumab with or without tremelimumab in combination with chemotherapy in first-line metastatic non-small-cell lung cancer: outcomes by tumor mutational burden in POSEIDON
First-line treatment with T (limited course) plus D (until progression) and four cycles of CT consistently improved clinical outcomes versus CT alone in both bTMB-high and -low subgroups, and also in both high and low tTMB subgroups, in patients with mNSCLC. Benefit appeared greater in the TMB-high versus TMB-low subgroups; the addition of anti-cytotoxic T lymphocyte-associated antigen-4 to anti-PD-L1 and CT seemed to increase the magnitude of this difference.
Authors
- H. Madison
- M.L. Johnson
- C. Lowery
- E.B. Garon
- R. Stewart
- Kelly S. Oliner
- Zengzhen Lai
- Solange Peters (ORCID: https://orcid.org/0000-0002-0412-7143)
- Anne L’Hernault
- Tony Mok (ORCID: https://orcid.org/0000-0002-8251-0551)
- Helen Mann
- M. Ratcliffe
Institutions
- AstraZeneca (United Kingdom) (GB)
- University of California, Los Angeles (US)
- Sarah Cannon Research Institute (GB)
- Chinese University of Hong Kong (HK)
- Centre Hospitalier Universitaire Vaudois (CH)
- Sarah Cannon (US)
- AstraZeneca (United States) (US)
Publication Details
- Journal
- ESMO Open
- Published
- 2025-05-01
- DOI
- https://doi.org/10.1016/j.esmoop.2025.105058
- Citations
- 2
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 2.09
Funders
- AstraZeneca